Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 3Phase 1 2

Status

Completed 11Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Cyclophosphamide 119Specimen Handling 104pembrolizumab 102Magnetic Resonance Spectroscopy 96fludarabine 92Biopsy 79Injections 53Nivolumab 41venetoclax 40Bevacizumab 40Fluorouracil 38Paclitaxel 37Cisplatin 36Cetuximab 35Carboplatin 35Gemcitabine 31fludarabine phosphate 30Radiotherapy 30Oxaliplatin 30Leucovorin 28Immunotherapy, Adoptive 25Drug Therapy 25Ipilimumab 24Azacitidine 23Irinotecan 21130-nm albumin-bound paclitaxel 21tislelizumab 20Temozolomide 20Radiation 20atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × PM 01183 × Clear all
NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
34 enrolled
Gynecologic

Ovarian Neoplasms

NCT05244239 2025-10-31

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Emory University

Phase 1 Recruiting
22 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡